Skip to main content

Peer Review reports

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Original Submission
24 May 2022 Submitted Original manuscript
9 Aug 2022 Reviewed Reviewer Report
26 Aug 2022 Reviewed Reviewer Report
6 Sep 2022 Reviewed Reviewer Report
8 Sep 2022 Reviewed Reviewer Report
10 Oct 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 2
10 Oct 2022 Submitted Manuscript version 2
11 Oct 2022 Reviewed Reviewer Report
12 Oct 2022 Reviewed Reviewer Report
15 Oct 2022 Reviewed Reviewer Report
24 Oct 2022 Reviewed Reviewer Report
2 Nov 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 3
2 Nov 2022 Submitted Manuscript version 3
4 Nov 2022 Reviewed Reviewer Report
4 Nov 2022 Reviewed Reviewer Report
5 Nov 2022 Reviewed Reviewer Report
16 Nov 2022 Author responded Author comments - Yuankai Shi
Resubmission - Version 4
16 Nov 2022 Submitted Manuscript version 4
Publishing
1 Dec 2022 Editorially accepted
8 Jan 2023 Article published 10.1186/s12916-022-02692-8

You can find further information about peer review here.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us